Author/Authors :
Sadeghi, Marjan Department of Biology and Anatomical Sciences - School of Medicine, Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Fadaee Fathabadi, Fatemeh Department of Biology and Anatomical Sciences - School of Medicine, Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Noorozian, Mohsen Department of Biology and Anatomical Sciences - School of Medicine, Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Niknazar, Somayeh Hearing Disorders Research Center - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Azimi, Hadi Department of English Language Teaching - School of Medicine - Shahid Beheshti University of Medical Sciences - Tehran, Iran
Abstract :
Background: Bone marrow stromal stem cells (BMSCs) are non-hematopoietic, stromal cellsthat can differentiate into mesenchymal and other type of tissues. The BMSCs have properties that make them ideal candidates for tissue engineering. The present study aimed to investigate the effect of deferoxamine (DFO) on homing of bone marrow-derived mesenchymal stem cell, and to examine if DFO can increase migration and subsequent homing of mesenchymal stem cells (MSCs) in vitro.
Methods: BMSCs were isolated from the long bones of NMARI rats through density gradientcentrifugation and adherent cell culture. Next, they were treated using DFO in Dulbecco’s modified eagle medium (DMEM) for 24 h. The expression of chemokine receptor 2 (CCR2) were assessed using RT-PCR.
Results: BMSCs expressed CCR2 on a large proportion of cells. In DFO-treated BMSCs,expression of CCR2 (P<0.005) significantly increased compared to that in control groups. Elevation and up regulation of CCR2 in DFO-treated MSCs were observed.
Conclusion: Preconditioning of BMSCs using DFO prior to transplantation could increasehoming of BMSCs through affecting some chemokine receptors as well as proteases involved and thus improve the efficacy of cell therapy.
